Skip to Content

Align Technology Inc ALGN

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Align Raises 2021 Revenue and Margin Guidance Following Strong Second-Quarter Earnings

Dylan Finley, CFA Equity Analyst

Analyst Note

| Dylan Finley, CFA |

No-moat Align reported strong results in the second quarter, with total revenue exceeding the $1 billion watermark for the first time, a 13% increase sequentially and 186% increase year over year. We plan to incorporate these results in our model, but upon this preliminary look we don’t expect to change our fair value estimate and no-moat rating. The substantial year-over-year growth can largely be attributed to weakness in the prior-year period when many practices closed during shelter-in-place orders at the onset of the COVID-19 pandemic. Top-line growth continues to be fueled by a strong consumer marketing effort, utilizing social media influencers to propel growth in both teen and adult markets.  Average selling price during the quarter was slightly impacted by higher discounts and credits offered to orthodontists and general practitioners, reflecting pressures from continued competition in the space. Following Align's positive second quarter financial results, management revised its 2021 revenue guidance to a range of $3.85 million-$3.95 million, up from a range of $3.70 million-$3.80 million, reflecting a strong outlook for the second half of 2021. Management also revised its outlook for GAAP operating margin, raising the guidance midpoint by 0.5% to 24.5%.

Read Full Analysis

Company Profile

Business Description

Align Technology is a medical (dental) device company primarily known for the Invisalign system, which is an alternative to traditional braces to correct a wide range of malocclusions. The company also manufactures intraoral scanners and computer-aided design/computer-aided manufacture digital services to support the customization of these liners. Historically, only orthodontists serviced this product, but more recently the company has expanded its direct marketing efforts to include generalists (dentists) and consumers.

Contact
410 North Scottsdale Road, Suite 1300
Tempe, AZ, 85281
T +1 408 470-1000
Sector Healthcare
Industry Medical Devices
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type Aggressive Growth
Employees 18,975

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.